

Korea DPR Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Korea DPR			
2. Grant number: 1920-PRK-18e-X / 19-PRK-08m-Y			
3. Date of Decision Letter: 22 March 2019			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), Measles-Rubella first and second dose routine 2D Routine			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2019 - 2020			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2019	2020	Total ²
Programme Budget (US\$)	87,000	329,500	416,500
10. Vaccine Introduction Grant (in US\$): 289,448 Payable up to six months before vaccine introduction.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³			
Type of supplies to be purchased with Gavi funds in each year	2019		
Number of Measles-Rubella vaccines doses	133,100		
Annual Amounts (US\$)	87,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations: Reference code: 1920-PRK-18e-X-C

According to the co-financing policy, DPR Korea falls within the initial self-financing group. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020
Number of vaccine doses	113,800	432,100
Number of AD syringes	0	0
Number of re-constitution syringes	0	0
Number of safety boxes	0	0
Value of vaccine doses (US\$)	72,769	276522
Total co-financing payments (US\$) (including freight)	74,500	281,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
22 March 2019